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Antiangiogenic and tumour inhibitory effects of
downregulating tumour endothelial FABP4
U Harjes1,8,9, E Bridges1,8, KM Gharpure2,8, I Roxanis3, H Sheldon1, F Miranda4, LS Mangala2,5, S Pradeep2, G Lopez-Berestein5,6,
A Ahmed4, B Fielding7, AK Sood2,5,6,10 and AL Harris1,10
Fatty acid binding protein 4 (FABP4) is a fatty acid chaperone, which is induced during adipocyte differentiation. Previously we have
shown that FABP4 in endothelial cells is induced by the NOTCH1 signalling pathway, the latter of which is involved in mechanisms of
resistance to antiangiogenic tumour therapy. Here, we investigated the role of FABP4 in endothelial fatty acid metabolism and tumour
angiogenesis. We analysed the effect of transient FABP4 knockdown in human umbilical vein endothelial cells on fatty acid metabolism,
viability and angiogenesis. Through therapeutic delivery of siRNA targeting mouse FABP4, we investigated the effect of endothelial
FABP4 knockdown on tumour growth and blood vessel formation. In vitro, siRNA-mediated FABP4 knockdown in endothelial cells led to
a marked increase of endothelial fatty acid oxidation, an increase of reactive oxygen species and decreased angiogenesis. In vivo, we
found that increased NOTCH1 signalling in tumour xenografts led to increased expression of endothelial FABP4 that decreased when
NOTCH1 and VEGFA inhibitors were used in combination. Angiogenesis, growth and metastasis in ovarian tumour xenografts were
markedly inhibited by therapeutic siRNA delivery targeting mouse endothelial FABP4. Therapeutic targeting of endothelial FABP4 by
siRNA in vivo has antiangiogenic and antitumour effects with minimal toxicity and should be investigated further.
Oncogene advance online publication, 29 August 2016; doi:10.1038/onc.2016.256
INTRODUCTION
The metabolism of fatty acids (FA) has been recognized as a key
process required for the formation of new blood vessels
(angiogenesis).1 FAs can be used for membrane and lipid
synthesis, regulation of gene expression and energy
production.2–5 Via the TCA cycle, the oxidation of FAs (FAO)
signiﬁcantly contributes to the de novo synthesis of nucleotides
during endothelial cell (EC) proliferation.1 Upon uptake and
release of FAs into the cell, FAs are either activated by acyl-CoA
synthases or bound by FA-binding proteins 1–9 (FABP1–9).
However, FAs, which are not converted to FA-CoA or bound to
FABPs, can cause cellular stress.6 Adipocyte FABP4 binds FAs and
provides feedback inhibition of lipolysis through interaction with
lipases. FABP4− /− adipocytes, in which this feedback inhibition is
lost, show higher lipolytic rates and higher levels of intracellular
free FAs.7,8 In addition, FABP4 delivers FAs to the nucleus to
activate peroxisome proliferator-activated nuclear receptor γ, a
main transcriptional inducer of adipocyte FA storage. FA
metabolism is deregulated in a number of cancers.5,9 Speciﬁcally,
FABPs are involved in tumour biology through their function in
regulation of PPAR activity and/or FA uptake and oxidation.3,4,10
Interestingly, in FABP4− /− mice, ovarian tumour xenograft
growth and metastasis were reduced.11 This was linked to
reduced utilization of adipocyte-derived FAs in tumour cells and
to reduced FABP4 expression in adipocytes and adjacent tumour
cells.11
Vascular endothelial growth factor A (VEGFA) is a major inducer
of tumour blood vessel growth (tumour angiogenesis). Indeed,
vessel density in ovarian tumours increases with tumour progres-
sion and correlates with expression of VEGF receptor 2.12
However, many ovarian tumours are not responsive to anti-
VEGFA therapies due to upregulation of alternative pathways. As
such, NOTCH1 signalling induction by its ligand Delta-like ligand 4
(DLL4), itself a target of VEGA, is associated with anti-VEGFA
resistance in ovarian cancer patients.13 NOTCH1 signalling limits
angiogenesis by modulating the VEGFA response, leading to
larger, better perfused tumour vessels, less hypoxia and reduced
response to VEGFA-targeting therapies.14 Target genes of NOTCH1
and VEGFA signalling, such as the NOTCH1 targets Jagged 1 and
HESR1 and the VEGFA target matrix metallopeptidase 9, are
upregulated in tumour-associated ECs from invasive ovarian
carcinoma.15 Dual targeting of DLL4/NOTCH1 and VEGFA signal-
ling is more effective than single therapy in orthotopic mouse
ovarian tumour models,16 making NOTCH1 and VEGFA signalling
an attractive target in ovarian tumour angiogenesis.
We have shown that in ECs, VEGFA upregulates FABP4
expression indirectly by inducing DLL4, which activates NOTCH1
signalling and initiates FABP4 gene transcription.17 However,
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tumour angiogenesis in FABP4− /− mice, and its relation to
NOTCH1/ VEGFA signalling pathways and endothelial FA meta-
bolism, has not been studied in detail.11 In this study, we aimed to
investigate the role of FABP4 in ovarian tumour angiogenesis and
in EC FA metabolism. We show that endothelial FABP4 expression
requires NOTCH1 and VEGFA signalling, and is required for ovarian
tumour angiogenesis. Furthermore, endothelial FABP4 silencing
led to deregulation of enzymes governing FA storage and lipolysis,
and increased the rate of FAO. FAO is required for vascular
sprouting and contributes to NADPH and reactive oxygen species
(ROS) scavenging in certain cell types.1,18 However, we found that
FABP4 silencing, while increasing FAO, led to decreased sprouting.
FABP4 silenced cells showed an increased mitochondrial mem-
brane potential, which was dependent on increased FAO. We
conclude that FABP4 is required for the regulation of free FA levels
in the cell to protect from FA-induced ROS production in ECs, and
that FABP4, a target of VEGF and NOTCH signalling, plays a
signiﬁcant role in the formation of tumour vasculature, controlling
ROS formation and intracellular FA trafﬁcking in FA-rich
environments.
RESULTS
Activation of endothelial NOTCH1 signalling in vivo induces FABP4
expression
We have previously shown that vessels in DLL4-overexpressing
U87 xenografts are larger, better perfused and the tumours less
hypoxic, due to increased NOTCH1 signalling in the vasculature.14
These xenografts were chosen to study tumour endothelial FABP4
expression in response to NOTCH1 signalling and NOTCH1/
VEGFA-targeting therapies in vivo. In these xenografts, we found
that more than 50% of the vessels in DLL4-overexpressing
xenografts showed a strong FABP4 expression compared with
10–20% of the vessels in the control (empty vector, EV) tumours
(Po0.00001) (Figures 1a and b). In tumours treated with
bevazicumab (BEV, antibody targeting VEGFA) or dibenzazepine
(DBZ, inhibits NOTCH1 signalling by inhibiting γ-secretase), FABP4
staining in the vessels of DLL4-overexpressing tumours was still
stronger and more extensive than in the vessels of EV tumours
(Po0.01 in BEV-treated, Po0.05 in DBZ-treated tumours). In
tumours treated with BEV and DBZ combined, vessels with strong
FABP4 staining were signiﬁcantly less than in dimethylsulphoxide-
treated DLL4-overexpressing tumours, and no difference to EV
tumours was observed (Figures 1a and b). This shows that tumour
endothelial FABP4 expression is induced by activation of NOTCH1
signalling, and can be targeted by inhibition of VEGFA and
NOTCH1 signalling.
Vascular FABP4 expression is associated with low-grade ovarian
cancer
Patients with advanced serous ovarian carcinoma show increased
expression of FABP4 in tumour cells metastasized to the omentum
compared with cells of the primary tumour.11 NOTCH1 and VEGFA
signalling are implicated in the progression of ovarian tumour
angiogenesis.12,13,15,16 However, studies investigating the expres-
sion in tumour vessels are lacking. We obtained tumour
microarrays of 16 low-grade and 51 high-grade serous ovarian
carcinomas and determined expression of FABP4 protein in
tumour vessels and tumour epithelial cells. Epithelial FABP4
expression in low-grade and high-grade carcinomas was similar in
intensity and extent. However, vascular FABP4 expression in low-
grade carcinomas was more than two-fold higher than FABP4 in
the vessels of high-grade tumours (Figures 2a–c).
Vascular FABP4 expression is highest in the stromal compartment
of ovarian tumours
We then studied the expression of FABP4 in vessels of high-grade
primary ovarian tumours and omental metastasis in more detail,
focusing on the intratumoural distribution of FABP4-positive
vessels. We observed that in the primary tumour, FABP4
expression in vessels within the stroma (Figures 2d and l) was
signiﬁcantly higher than in vessels directly adjacent to tumour
cells (Figures 2e and l) and vessels in the tumour–stroma interface
(Figures 2f and l). Vascular FABP4 expression in the stroma of the
primary tumour was also signiﬁcantly higher than in the stroma of
Figure 1. DLL4-overexpressing glioblastoma xenografts show
increased vascular FABP4 expression that is sensitive to drug inhibition
of NOTCH1 and VEGFA signalling. Formaldehyde ﬁxed-parafﬁn
embedded sections of empty vector (EV) control or DLL4-
overexpressing U87 xenografts treated with vehicle control (dimethyl-
sulphoxide, DMSO), the VEGFA-antibody bevacizumab (BEV) and/or the
γ-secretase inhibitor dibenzazepine (DBZ, inhibits NOTCH1 signalling)
were stained for FABP4 using a mouse and human speciﬁc antibody
(a), and vascular FABP4 staining (red arrow) was quantiﬁed. The
percentage of strongly positive vessels is shown (b). Scale bar=100 μM,
n=5 per group, *Po0.05; **Po0.01; ****Po0.00001. Error bars, s.d.
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Figure 2. Vessels of low-grade serous ovarian carcinoma show overall strongly positive FABP4 expression. Tissue microarrays of low- and high-
grade ovarian serous carcinoma immunohistochemistry were performed for FABP4 using a mouse and human speciﬁc antibody ((a) low-grade
and (b) high-grade; vessels are indicated with a red arrow, epithelial cells with a green arrow), and vascular FABP4 staining was quantiﬁed. The
average combined score of intensity and extent of vascular versus epithelial FABP4 expression is shown (c). Paired patient samples of primary
and metastatic serous ovarian carcinoma were selected and immunohistochemistry was performed for FABP4. Intensity and extent of vascular
FABP4 expression (red arrow) were quantiﬁed in vessels of the stroma (s) ((d) primary tumour and (g) metastatic tumour), within the tumour
epithelium (t) ((e) primary tumour and (k) metastatic tumour), within tumour–stroma interface (ts) ((f) primary tumour and (h) metastatic
tumour), the fat tissue (f ) (j), the tumour–fat interface (tf ) (i) of the primary and metastatic tumour. The average combined score of intensity
and extent of vascular FABP4 expression in these different compartments is shown (l) and compared with NOTCH1, DLL4 and VEGFR2
expression in compartments of the primary tumour (m). Scale bar= 100 μM, n = 7 paired samples, *Po0.05; **Po0.01; ***Po0.0001,
****Po0.00001. Error bars, s.d.
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omental metastasis (Figure 2g). In omental metastasis, we
observed similar FABP4 expression in the vessels of the stroma
(Figure 2g), the tumour–stroma interface (Figure 2h) and the
tumour–fat interface (Figure 2i). The expression of FABP4 in
vessels of the fat tissue distant from the tumour (Figure 2j) was
signiﬁcantly higher than in vessels directly adjacent to tumour
cells (Figure 2k).
These data show that FABP4 expression was highest in stroma-
and fat tissue-embedded vessels, in which proangiogenic signals
coming from the tumour might be less prominent. Indeed, in the
stromal regions of the primary tumour, the vascular expression of
cleaved NOTCH1 (NOTCH1 intracellular domain, NICD, indicates
active NOTCH1 signalling) correlated with FABP4 expression,
whereas in vessels within the tumour and the tumour–stroma
interface this correlation was lost. Instead, components of the VEGF
signalling pathway were more prominent, with DLL4 and VEGFR2
being more highly expressed (Figure 2m, representative images
shown in Supplementary Figure S1).
Mouse FABP4 knockdown decreases ovarian tumour xenograft
growth and microvessel density
FABP4 expression was highest in vessels of low-grade serous
carcinoma, and in the stromal compartment of advanced serous
carcinoma, challenging the question whether tumour endothelial
FABP4 expression is required for tumour progression. Previous
studies have not investigated the effect of endothelial FABP4
knockdown (KD) on tumour angiogenesis and tumour growth.11
We utilized the chitosan-nanoparticle drug delivery system,
which has a high potential for clinical application, to deliver two
different small interfering RNA (siRNA) sequences targeting mouse
FABP4 (Supplementary Figure S3) in an orthotopic model of
ovarian carcinoma.19,20 This system efﬁciently targets blood
vessels without affecting other stromal cells such as inﬁltrating
macrophages.19 By using the chitosan-nanoparticle system, we
were able to achieve efﬁcient silencing of FABP4 in the tumour
vessels while not affecting FABP4 expression in stromal or adipose
cells (Supplementary Figure S3).
We observed a signiﬁcant inhibition of tumour growth with
mouse FABP4 KD; a o70% reduction of tumour weight and
number of tumour nodules with both siRNA treatments
(Figure 3a). Strikingly, microvessel density was reduced by
450% with both treatments compared with the control
(Figure 3b). No consistent effects on macrophage inﬁltration were
detected (Figure 3c). Ki67 as a marker for proliferation was
signiﬁcantly downregulated in tumour cells grown in xenografts
treated with siFABP4 (Figure 3d). There was signiﬁcantly reduced
hypoxia in siFABP4-treated tumours (Figure 3e). This was
accompanied by a reduction of necrotic areas (Supplementary
Figure S4), which is likely a result of the decrease in tumour size
and support of the viable rim by existing host blood vessels. The
expression of the pericyte marker neural/glial antigen 2 (NG2)
showed no signiﬁcant change in the treated xenografts (Figure 3f).
FABP4 silencing reduces endothelial sprout elongation in vitro
The interplay of VEGF and DLL4–NOTCH1 signalling pathways
controls vascular sprouting, that is, DLL4–NOTCH1 limits the VEGF-
induced migratory tip cell phenotype and enables the elongation
of the sprout via induction of the more proliferative stalk cell
phenotype. Inhibition of VEGF signalling abrogates sprout
formation, whereas inhibition of NTOCH1 signalling leads to
enhanced tip cell formation but reduced sprout elongation.21
FABP4, being a target of both VEGF and NOTCH, may be required
for vascular sprouting. Indeed, FABP4 silencing by siRNA in human
umbilical vein endothelial cells (EC) led to a reduction of vascular
sprouting. While sprout number was overall not affected or
slightly increased, we observed a signiﬁcant reduction of sprout
length by 50% (Figure 4a). EC migration was overall not
consistently changed in FABP4 silenced ECs (Figure 4b), contrary
to previous reports.22 EC proliferation, required for elongation of
the sprout, was signiﬁcantly decreased in FABP4 silenced ECs
(Figure 4c). Since this was accompanied by increased cell death
(Figure 4d), the sprouting defect is likely due to a decreased
capacity of FABP4 silenced ECs to elongate the sprout.
FABP4 silencing increases endothelial FAO in vitro
FABP4 has been implicated in the transport and release of FAs
from lipid stores, by providing feedback inhibition to hormone-
sensitive lipase (HSL) when intracellular free FAs are abundant,
and by downregulating PPARG mRNA expression.7,23 When FABP4
was silenced in ECs (Figures 5a and b) we detected relatively
decreased levels of serine 565 phosphorylation, inhibiting HSL
activity (Figure 5b), and relatively increased levels of serine 660
phosphorylation, stimulating HSL activity (Figure 5b), indicating
overall increased activity of HSL (Figure 5b).
An increase of lipolysis is likely to result in depletion of
intracellular lipid stores. Vice versa, increased lipolysis may lead to
a toxic increase of intracellular free FAs and upregulation of rescue
mechanisms, such as activation of lipid synthesis and storage.
Channelling of FAs into lipid stores can prevent toxic levels of
intracellular free FAs. Indeed, we detected upregulation of PPARG
mRNA expression, pointing to an activation of FA storage
(Figure 5c). However, the levels of lipid stores remained
unchanged in FABP4 silenced ECs (Figure 5d). Furthermore,
we investigated the uptake and accumulation of FAs in
ECs by measuring intracellular accumulation of exogenous
[U14C]-oleic acid. However, FABP4 silencing had no effect on the
accumulation of intracellular [U14C]-oleic acid (Figure 5e). Excess
intracellular FAs can also be eliminated by degradation through
FAO. To test this, we measured the rate of oxidation of [U14C]-
labelled oleic acid in FABP4 silenced conditions. Indeed, FABP4
silencing led to an increase of FAO by 40%, which was reversed by
etomoxir, an inhibitor of FA import into the mitochondria
(Figures 5f and g).
FABP4 silencing causes increased ROS production
ECs with FABP4 KD exhibited signs of cellular damage. Since
increased mitochondrial respiration and abnormally increased
FAO can lead to an increase of mitochondrial ROS,24 causing
cellular toxicity, we quantiﬁed total and mitochondrial ROS levels
in FABP4 KD ECs. We treated ECs with the superoxide dismutase
mimetic MnTMPyP to scavenge mitochondrial ROS and/or
etomoxir to inhibit FAO. Indeed, FABP4 silencing led to a
two-fold increase of total ROS, which was partly reversed by
MnTMPyP. Total ROS were not rescued by etomoxir treatment
(Figure 6a). Mitochondrial ROS were signiﬁcantly increased by
20–30% in FABP4 KD ECs, which was completely reversed by
MnTMPyp. The increase in mitochondrial ROS in FABP4
silenced conditions was not observed when FAO was inhibited
(Figure 6b).
Mitochondrial ROS production can lead to decreased mitochon-
drial function and cytosolic oxidation, contributing to cellular
damage. Mitochondrial ROS are produced from the leakage of
electrons passing through the electron transport chain during
mitochondrial respiration, which leads to partial reduction of
oxygen to produce superoxide at complex I and II, and
subsequent superoxide dismutation to H2O2 by superoxide
dismutase. While superoxide can hardly pass the outer mitochon-
drial membrane, H2O2 can be transported into the cytosol and
lead to oxidative modiﬁcations. Electron transport chain activity is
coupled to the pumping of protons, leading to the formation of
the mitochondrial membrane potential (ΔΨm). At higher ΔΨm ROS
production increases exponentially.25 We measured ΔΨm to
determine mitochondrial integrity in conditions of FABP4 KD
and FAO inhibition. Seventy to eighty percent of untreated control
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Figure 3. Therapeutic siRNA-mediated knockdown of FABP4 in the mouse stroma decreases tumour growth and tumour angiogenesis.
Chitosan-nanoparticle delivery of two siRNA sequences targeting mouse FABP4 was carried out in mice bearing SKOV3 ip2 orthotopic
xenografts. Number of tumour nodules and tumour weight were determined (a), and immunohistochemistry for CD31 (b), CD68 (c), Ki67 (d),
CA9 (e) and NG2 (f) was performed on tumour formaldehyde ﬁxed-parafﬁn embedded sections and quantiﬁed. Scale bar= 100 μM. n= 10 per
group, *Po0.05; **Po0.01; ****Po0.00001. Error bars, s.e.m.
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Figure 4. FABP4 knockdown reduces vascular sprout elongation and endothelial cell viability. Human umbilical vein endothelial cells (EC) were
transfected with non-targeting control siRNA or two different sequences of siRNA targeting FABP4 (20 nM, pooled or single as indicated). To
determine vascular sprouting, transfected or ECs were grown as spheroids in hanging drops and embedded in matrigel, and sprout number
and length were quantiﬁed after 48 h. n = 4 (a). To determine migration, scratched conﬂuent monolayers were monitored for % wound closure
over time (b). To measure cell number as an indicator for proliferation, ECs transfected with pooled siRNA sequences #1 and #2 targeting
FABP4 were grown for 72 h, trypsinized and counted. n= 3 (c). Cell viability was determined in the same samples based on cell membrane
permeability for trypan blue. n = 4 (d). *Po0.05; **Po0.01; ***Po0.001. Error bars, s.d.
Figure 5. FABP4 knockdown regulates fatty acid metabolism enzymes and increases fatty acid oxidation. Human umbilical vein endothelial
cells (EC) were transfected with non-targeting control siRNA or two different sequences of siRNA targeting FABP4 (20 nM) and mRNA
expression of FABP4 and PPARG were determined and are expressed relative to β-actin (ACTB). n= 5 (a, b). Protein levels of FABP4,
phosphorylated HSL (Serine 565, p565, inhibitory; Serine 660, p660, activating) and total HSL were analysed in response to FABP4 knockdown
by immunoblot analysis, using β-actin as a loading control. Band densitometry analysis of phosphorylated HSL was carried out relative to total
HSL. n = 3 (c). To measure lipid droplet accumulation, transfected ECs were exposed to media containing BSA or oleic acid (OA, serving as a
positive control) conjugated to BSA for 16 h prior to staining lipid droplets with the ﬂuorescent dye LD540 and measuring signal intensity in
the ﬂuorescein isothyanate (FITC) channel by FACS analysis. n= 3 (d). Fatty acid uptake and oxidation were measured by detecting intracellular
14C or 14CO2 derived from [U14C]-labelled OA in the cell culture media. n= 4 (e–g). FAO rates were corrected for the levels of FAs taken up into
the cells. Etomoxir (50 μM, Eto) or dimethylsulphoxide (DMSO) were added 16 h after the transfection to inhibit fatty acid oxidation n= 3
(g) *Po0.05; **Po0.01; ***Po0.001. Error bars, s.d.
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cells had a medium ΔΨm (represented by R1), which was
signiﬁcantly decreased by FAO inhibition and/or FABP4 KD
(Figures 6c and d (right panel)). This change was due to (1) an
increase of low ΔΨm cells (represented by R2), likely due to
activation of apoptosis (Figure 6d, middle panel) and (2) an
increase of high ΔΨm cells (represented by upper R1) (Figure 6d,
left panel). Indeed, when FABP4 was silenced, we observed a
signiﬁcant increase of high ΔΨm cells (Figure 6d, left panel).
Etomoxir partially rescued the high ΔΨm in FABP4 silenced cells.
The occurrence of high ΔΨm cells in FABP4 silenced conditions ﬁts
the observed increase in mitochondrial ROS, which likely originate
from increased FAO and mitochondrial respiration.
DISCUSSION
In this study, we investigated FABP4 in EC metabolism and
function, and its potential as a therapeutic target in antiangio-
genic therapies. Therapeutic delivery of siRNA led to reduced
endothelial FABP4 expression and signiﬁcant reduction of tumour
growth. In vitro, FABP4 KD led to activation of lipolysis and a
signiﬁcant increase of FAO, causing increased ΔΨm and mitochon-
drial ROS production.
Endothelial FABP4 expression in normal and tumour tissues of
ovary and brain has been reported.11,26 It has been shown
previously only that adipocyte FABP4 expression is important for
promoting ovarian carcinoma.10 We observed that endothelial
Figure 6. FABP4 knockdown leads to upregulation of reactive oxygen species (ROS) and mitochondrial membrane potential (ΔΨm). For ROS
measurements, transfected samples were treated with etomoxir (Eto, inhibits mitochondrial fatty acid import) and/or the superoxide
dismutase mimetic manganese (III) tetrakis(1-methyl-4-pyridyl)porphyrin pentachloride (MnTMPyP, 12.5 μM) or dimethylsulphoxide (DMSO) as
a vehicle control for 72 h. Total ROS were measured by using 5-(and-6)-chloromethyl-2′,7′-dichlorodihydroﬂuorescein diacetate (CM-
H2DCFDA; Life Technologies). n= 3 (a). Mitochondrial ROS were measured by FACS using MitoSOX Red mitochondrial superoxide indicator
(Life Technologies). n= 3 (b). Representative images of FACS analysis and gating strategy of JC1 staining to determine ΔΨm are shown. JC1 is a
cationic dye that forms aggregates, exhibiting a green-to-red shift when the ΔΨm is increased. The upper R1 quadrant represents high ΔΨm,
R1 represents medium ΔΨm and R2 represents low ΔΨm (c). Quantiﬁcation of biological replicates is shown. n= 5 (d). *Po0.05; **Po0.01;
***Po0.001. Error bars, s.d.
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FABP4 expression in vivo was enhanced in DLL4-overexpressing
tumour xenografts, demonstrating the in vivo induction of FABP4
directly by NOTCH1 signalling. DLL4-overexpressing tumours have
increased perfusion and are insensitive to BEV treatment, as
described previously.14 Importantly, endothelial FABP4 expression
was insensitive to VEGFA inhibition alone, but was reduced when
inhibition of NOTCH1 and VEGFA signalling was combined. This
may indicate that apart from direct NOTCH1-mediated induction of
FABP4, other pathways are important for the maintenance of FABP4
expression in vivo. VEGFA and DLL4/NOTCH1 blockade by BEV and
DBZ increases tumour hypoxia.14 Interestingly, mRNA expression of
FABP4 was downregulated in hypoxia in vitro (data not shown).
Thus increased hypoxia in combined BEV and DBZ-treated tumours
in vivomay be contributing to reduced FABP4 expression. As FABP4
is a key gene downstream of DLL4/NOTCH1 and indirectly of VEGF,
by targeting it we may overcome NOTCH1-mediated resistance in a
less toxic way than by using γ-secretase inhibitors.27
FABP4 was more abundant in vessels of low-grade than high-
grade ovarian carcinomas. Recent studies on the effect of BEV in
ovarian cancer have shown improvement of progression-free
survival (39 vs 34 months), but not overall survival.28 Even good
prognosis groups showed 74% progression at a median time of
17 months from the start of treatment and a median survival of
27 months. In a subgroup analysis it was found that patients with
low-grade carcinoma and less aggressive tumour features showed
reduced beneﬁt from BEV treatment compared with those in the
more aggressive, high-grade group.28 Based on our observations,
tumours of the low-grade subgroup are likely to have high
endothelial FABP4 expression. This subgroup could potentially
beneﬁt from FABP4 inhibition.
In high-grade carcinomas, FABP4 was speciﬁcally expressed in
stroma-rich regions, whereas vessels directly adjacent to tumour
cells did not express FABP4. The tumour architecture is a
determinant of resistance to antiangiogenic therapy.29 Tumours
in which nests of tumour cells are surrounded by well-developed
stromal structures containing the majority of the vessels are less
responsive to single therapies targeting VEGFA, compared with
tumours in which the vessels are embedded in the tumour mass.
Thus, the stroma separates tumour cells from the vessels,
potentially creating more mature vessels.29 NOTCH1, known
for its limiting and stabilizing effect on angiogenesis, was
co-expressed with FABP4 in these stromal regions, potentially
promoting a more mature vasculature, and resistance to VEGFA-
targeting therapies.
Previous work highlighted the role of FABP4 in adipocytes and
adjacent ovarian cancer cells11 but a role of FABP4 in tumour
vessels has not been studied directly. Nieman et al.,11 who studied
ovarian tumour growth in FABP4− /− mice, attribute the
decreased tumour burden solely to the lack of FABP4 expression
in adipocytes and decreased FA metabolism in adjacent cancer
cells. The researchers observed decreased microvessel density in
tumours; the importance of endothelial FABP4 was, however, not
investigated in that study.11 Our results show that siRNA-mediated
FABP4 silencing in the vessels, while maintaining FABP4 in
adipose tissue, leads to substantial loss of vessels and reduced
tumour growth. This, in addition to effects of FABP4 on FA
metabolism and mitochondrial ROS in ECs in vitro, strongly
supports a role of FABP4 in tumour angiogenesis.
Adipocytes of FABP4− /− mice have decreased rates of lipolysis
and accumulate intracellular free FAs.8 Endothelial FABP4 pre-
serves the controlled metabolism of FAs in ECs, by keeping the
intracellular release and degradation of FAs in balance (Figure 7).
We show for the ﬁrst time that HSL, a key lipolytic enzyme, is
highly expressed in ECs. The expression of endothelial FABP4 was
required for controlling HSL and thus lipolytic activity. Similarly,
PPARG mRNA induction in FABP4 KD cells may have represented
an attempt to (a) compensate for a lack of activating ligands or (b)
channel excess free/unbound FAs into lipids.
FABP4 silenced cells have increased FAO. This may serve to
remove excess free FAs resulting from increased lipolytic activity
when FABP4 is lacking. We further hypothesize that activated FAO
in FABP4 KD ECs is directly contributing to increased mitochon-
drial ROS production. The increased oxidation of FA leads to a
higher ΔΨm, indicating enhanced electron transport chain activity,
electron leakage and oxygen reduction. Since total ROS produc-
tion was only partially inhibited by the superoxide dismutase
mimetic MnTMPyP, FABP4 loss may generate cytoplasmic ROS
also by increasing the levels of unbound FAs, leading to activation
of ROS generators such as NADPH oxidases in the cytoplasm.6,30
An increase of ROS production may reduce the ability of ECs to
proliferate, sprout and form vascular networks.
Our data show that FABP4 is required for angiogenesis and an
important target in tumour angiogenesis, especially in tumours
that are low grade, rich in stroma and embedded in FA-rich
tissues. RNA-based therapies that enable tissue-speciﬁc delivery
are currently being tested in clinical trials.31 Our study provides a
rationale for testing vascular endothelium-targeted delivery plat-
forms with FABP4 siRNA to inhibit tumour growth.
MATERIALS AND METHODS
Cell culture
All cells were routinely tested for mycoplasma contamination. Primary
human umbilical ECs were purchased from Lonza, Visp, Switzerland and
cultured in endothelial growth medium 2 (Lonza). At least three different
pools of 3–5 donors were used for experiments. SV40-transformed mouse
Figure 7. Proposed model for functional mechanism. When FABP4 is
expressed in blood vessels (control), FABP4 binds to intracellular free/
unbound fatty acids (FA), and provides feedback inhibition to
hormone-sensitive lipase (which is phosphorylated at sites regulating
both inhibition and activation of HSL, HSL-Pinh/act) by controlling the
balance between lipolysis, FA uptake and oxidation (entry of FA into
mitochondria via carnitine-palmitoyl transferase 1a, CPT1a). When
FABP4 is knocked down (FABP4 KD), free/unbound fatty acids in the
cell are in excess. FABP4 loss leads to increased lipolysis, indicated by
increased activating phosphorylation of HSL (HSL-PACT), likely
resulting in increased free FA availability. This leads to upregulation
of rescue mechanisms such as the increase of the rate of FA oxidation
(FAO) and potentially tricarboxylic acid (TCA) cycling and oxidative
phosphorylation. Consequently, FABP4 loss is accompanied by
increased mitochondrial and total ROS production and decreased
cell viability, leading to reduced angiogenic activity and tumour
growth, but no change in macrophage (dark blue) inﬁltration in vivo.
The reduced tumour size is accompanied by less hypoxia and
necrosis (in grey) in the tumour.
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ECs (SVEC4-10) were from ATCC (Manassas, VA, USA). SKOV3 cells used to
obtain SKOV3 ip2 cells were from ATCC and cell line authentication was
routinely performed.
RNA interference
Reverse transfection of siRNA duplexes (20 nM) was performed using
Lipofectamine RNAiMax (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Two different ON-TARGETplus siRNAs target-
ing FABP4 (Dharmacon, Lafayette, CO, USA) were used (#1, targets 5′-
AUACUGAGAUUUCCUUCAU-3′; #2, targets 5′-GGUGGAAUGCGUCAUGAAA
-3′) and the ON-TARGETplus non-targeting pool (Dharmacon).
Gene expression analysis
RNA extraction was performed using Trizol reagent (Invitrogen) according
to the manufacturer’s instructions. Reverse transcription (RT) was
performed using the High Capacity cDNA RT kit (Applied Biosystems, Life
Technologies, Bleiswijk, Netherlands). QrtPCR was performed using the
SensiFAST SYBR No-ROX Kit (Bioline, London, UK). Raw data were analysed
using the 2(−ΔΔct) method, using ACTB as a housekeeping gene. QrtPCR
primer sequences (Invitrogen) were hFABP4 (forward 5′-ACGAGAGGATG
ATAAACTGGTGG-3′, reverse 5′-GCGAACTTCAGTCCAGGTCAAC-3′); hPPARG
(forward 5′-GGGGTGATGTGTTTGAACTTG-3′, reverse 5′-GACAGGAAAGAC
AACAGACAAATC-3′); mFABP4 (forward 5′- GGATGGAAAGTCGACCACAA-3′,
reverse 5′-TGGAAGTCACGCCTTTCATA-3′) and ACTB (forward 5′-GAGGAG
GCACCGGTAAATG-3′, reverse 5′-GTCACTCACTGGGACATAGGC-3′).
Protein expression analysis
Immunoblotting was performed using the Novex NuPAGE SDS-PAGE Gel
and blotting system (Invitrogen). Antibodies were anti-total HSL, anti-p565
HSL and anti-660 HSL (sampler kit #8334; Cell Signalling Technology, NEB,
Herts, UK), anti-FABP4 (HPA002188; Sigma-Aldrich, St Louis, MO, USA) and
anti-β-actin-peroxidase (Sigma-Aldrich).
FA accumulation and oxidation assay
Brieﬂy, FA accumulation and oxidation were measured in HUVEC in
endothelial growth medium 2 containing 50 μM carnitine and 500 μM
bovine serum albumin-conjugated oleic acid (OA, both Sigma-Aldrich), and
0.5 μCi/ml [U-14C]-OA (Perkin Elmer, Boston, MA, USA). To measure FA
accumulation, cells were lysed after 3 h of incubation. To measure FAO, 3 N
KOH, in a separate container that was inserted into the tissue culture ﬂask,
was used to capture CO2. Sixty per cent perchloric acid (Sigma-Aldrich) was
injected to capture intracellular CO2, as described previously.
10 Etomoxir
(50 μM; Sigma-Aldrich) was used to inhibit FAO.
Lipid droplet quantiﬁcation by FACS
Neutral and polar lipids in PFA-ﬁxed cells were stained with the ﬂuorescent
dye LD540 (kindly supplied by Dr C Thiele, LIMES Life and Medical Sciences
Institute, Bonn, Germany) and analysed by ﬂow cytometry.
Cell viability assay
Transfected cells were exposed to 10% Trypan blue solution (Life
Technologies, Carlsbad, CA, USA). Total cell number and trypan blue
positive cells were determined using the Cellometer Auto T4 cell counter
and software according to the manufacturer’s instructions (Nexcelom
Bioscience LLC, Lawrence, MA, USA).
Measurement of total and mitochondrial ROS
Total ROS levels were determined by 2′,7′-dichlorodihydroﬂuorescein
diacetate (H2-DCFDA; Life Technologies); mitochondrial ROS levels were
determined by MitoSOX (Life Technologies). ROS content was measured by
ﬂow cytometry. Manganese (III) tetrakis(1-methyl-4-pyridyl)porphyrin
pentachloride (MnTMPyP, 12.5 μM) was from Santa Cruz Biotechnology
(Dallas, TX, USA).
Measurement of mitochondrial membrane potential (ΔΨm)
ΔΨm was measured using the BD MitoScreen (JC-1) kit (BD Biosciences,
Franklin Lakes, NJ, USA) according to the manufacturer’s instructions. JC1 is
a cationic dye that accumulates in the mitochondria, driven by ΔΨm.
Brieﬂy, cells were grown as indicated and incubated in 1.25 μM JC1 and
analysed by ﬂow cytometry. The gating strategy was based on the
presence of three cell populations with high (upper R1) versus medium
(R1) versus low (R2) emission in the PE channel.
Scratch wound assay
HUVEC were grown to conﬂuence on ImageLock 24-well plates (Essen
BioScience, Ann Arbour, MI, USA). The scratch was introduced with a
woundmaking tool (WoundMaker; Essen BioScience) and imaged with the
Incucyte (Essen BioScience). The percentage of wound closure relative to
the control (70–80% closure) was measured.
Sprouting assay
HUVEC spheroids were grown in hanging drops containing 2.5 mg/ml
methylcellulose (Sigma-Aldrich), embedded in Gibco Geltrex Basement
Membrane Matrix (Life Technologies) and incubated for 48 h.
Immunohistochemistry
Parafﬁn-embedded cell pellets or tissue sections were retrieved, dewaxed
and rehydrated according to standard procedures. m/hFABP4 was stained
with anti-FABP4 (HPA002188; Sigma-Aldrich) (Supplementary Figure S2),
mFABP4 in FABP4-siRNA-treated xenografts was stained with anti-FABP4
(D25B3; Cell Signalling Technology). Others were rabbit Ki67 (M7240; Dako,
Glostrup, Denmark), rabbit CA9 (M75; BD Biosciences) and goat NG2
(ab101808; Abcam, Cambridge, UK), CD31 and CD68 (BD Biosciences).
Expression of CA9, Ki67 and NG2 was quantiﬁed on whole sections by
using ImageJ software (US National Institutes of Health, Bethesda, MD,
USA). Expression of CD31 and CD68 was quantiﬁed by using 15 random
ﬁelds of slides at ×100 magniﬁcation.
DLL4-overexpressing U87-xenograft selection and scoring
Formaldehyde ﬁxed-parafﬁn embedded sections of full sets of EV and
DLL4-overexpressing U87 xenografts treated with DBZ and/or BEV were
obtained as described previously (n= 5 per group).14 Vascular FABP4 was
scored and a combined intensity and extent quick score was calculated.
Serous ovarian tumour sample selection and scoring
Tissue microarrays of serous borderline and high-grade ovarian carcinomas
and samples of paired primary and metastatic serous ovarian carcinoma
were collected prospectively within a translational study that was ethically
approved (Number 11/SC/014, Berkshire NRES Committee) and all subjects
gave informed consent as appropriate. Vascular FABP4 in tissue micro-
arrays was scored by Dr Ioannis Roxannis, Oxford University Hospitals, and
a combined intensity and extent quick score was calculated. Vascular
FABP4 in paired samples was scored using Aperio ImageScope and IHC
Image analysis software (Leica Biosystems, Milton Keynes, UK), reporting
the normalized strong positive score.
Orthotopic in vivo model of ovarian cancer
Eight- to 12-week-old female athymic nude mice (NCr-nu) were purchased
from Taconic farms (Hudson, NY, USA) and cared for in accordance with
the guidelines set up by the American association for Accreditation of
Laboratory Animal care and the U.S. Public health Service Policy on Human
care and Use of Laboratory Animals. All in vivo experiments and protocols
were approved by MD Anderson’s Institutional Animal care and Use
Committee. For SKOV3 ip2 cell injections, 1 × 106 cells were injected
directly into the ovary.
Control or mouse FABP4 siRNAs (#1, target sequence 5′-CCGAG
AUUUCCUUCAAACU-3′; #2, target sequence 5′-ACCAUCCGGUCAGAG
AGUA-3′; supplementary #1, target sequence 5′-GGAAGGUGAAGAGCAU
CAU-3′; supplementary #2, target sequence 5′-CUGGGCGUGGAAUUCGAUG-3′;
from Sigma-Aldrich) were incorporated in chitosan nanoparticles as
described previously.19 Brieﬂy, chitosan was dissolved in 0.25% acetic
acid. The nanoparticles were spontaneously formed after adding
tripolyphosphate (0.25% w/v) and siRNA (1 μg/μl) under constant
stirring at room temperature. The nanoparticles were incubated for
40 min at 4 °C, centrifuged at 12 000 r.p.m. for 40 min at 4 °C and stored at
4 °C until use.
Twice weekly injections of 3.5 μg/100 μl control siRNA-CH, sequence
#1-CH and sequence #2-CH were started after 1 week (10 mice/group).
The mice were observed daily for adverse effects and killed when any of
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the mice seemed moribund. Mouse weight, tumour weight and number of
nodules were noted. Tissue specimens were ﬁxed with formalin or were
snap frozen.
Statistical analysis
Results are expressed as mean± standard deviation (s.d.) or standard error
of the mean (s.e.m.) as indicated. In vitro experimental data are shown as
mean of at least three biological replicates. For animal experiments, 10
mice were assigned per treatment group. This sample size gave 80%
power to detect 50% reduction in tumour weight with 95% conﬁdence.32
After tumour inoculation, mice were randomly allocated into treatment
groups. Mice that did not develop tumours were excluded from the
analyses, unless otherwise mentioned. Investigators were blinded as to on
which group they were performing necropsy. Statistical analysis was
performed using one-way analysis of variance (ANOVA) and Holm–Sidak’s
multiple comparison test to compare groups of more than two, or two-
sided Student’s t-test to compare two groups (GraphPad Prism 6, La Jolla,
CA, USA). It was assumed that the sampling distribution of the mean was
normal. Variances were similar between groups that were statistically
compared. Po0.05 was considered statistically signiﬁcant.
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